Oct 15th 2012 - Edison Investment Research today published a report on Bhp Billiton (BLT.L, LSE:BLT, LON:BLT) entitled "Deal Focused On HCV". In summary, the report says:
Benitec’s acquisition of its US-based technology licensee, Tacere Therapeutics, allows the Australian RNAi specialist to bring in-house a Phase I-ready drug candidate for Hepatitis C virus (HCV) infection. The transaction (of 102m shares, plus a potential cash royalty based on future licensing revenue) values Tacere at US$1.5m, hence it would appear to be a very attractive price.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »